Vancouver biotech company AbSci announced its intention to file for an initial public offering on Wednesday.
AbSci filed a registration statement relating to the proposed offering with the U.S. Securities and Exchange Commission, but it has not yet become effective, according to a Wednesday press release.
It will join the Nasdaq Global Market under the symbol ABSI, but the number of shares and price of the stock have not yet been determined.
The company engineers microorganisms called E. coli to produce proteins for pharmaceutical companies that use them to efficiently manufacture drugs, including insulin.
